An official website of the United States government
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
Trial Status: enrolling by invitation
This study will assess the long-term safety and efficacy of bilateral intra-parotid
administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late
xerostomia.
Inclusion Criteria
Received study drug in Study MGT-AQP1-201
Exclusion Criteria
Withdrew consent to participate in Study MGT-AQP1-201.
Additional locations may be listed on ClinicalTrials.gov for NCT06544798.
Locations matching your search criteria
United States
Iowa
Iowa City
University of Iowa/Holden Comprehensive Cancer Center
Status: Approved
Name Not Available
Maryland
Baltimore
Johns Hopkins University/Sidney Kimmel Cancer Center
Status: Active
Name Not Available
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: Active
Name Not Available
Individual participation in this study will last approximately 48 months for participants
who received AAV2-hAQP1 in Study MGT-AQP1-201 and at least 60 months for participants who
